



## Colorectal Cancer: MMR: MOLECULAR ONCOLOGY TUMOR BOARDS

### COURSE REFERENCES

Fujiyoshi K, Yamamoto G, Takahashi A, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. *Oncol Rep.* 2017;37:785-792. ([View Abstract](#))

Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Genetic/Familial High-Risk Assessment: Colorectal. Version 3. 2017-Oct 10, 2017 ([https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf)).

Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Colon Cancer. Version 1. 2018-January 18, 2018 ([https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf))

Molecular Biomarkers for the Evaluation of Colorectal Carcinoma: Guideline from the ASCP-CAP-AMP-ASCO. [www.cap.org/web/home/protocols-and-guidelines](http://www.cap.org/web/home/protocols-and-guidelines).

Cejas P, Lopez-Gomez M, Aguayo C, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. *Curr Cancer Drug Targets.* 2012;12:124-131. ([View Abstract](#))

Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol.* 2012;30:2956-2962. ([View Abstract](#))

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockage. *Science.* 2017;357:409-413. ([View Abstract](#))